MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1136/heartjnl-2020-318758

Медицинская библиотека · Heart (British Cardiac Society) · 2021

Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.

Dagenais Gilles R, Dyal Leanne, Bosch Jacqueline J, Leong Darryl P, Aboyans Victor, Berkowitz Scott D, Bhatt Deepak L, Connolly Stuart J, Fox Keith A A, Muehlhofer Eva, Probstfield Jeffrey L, Widimsky Petr, Winkelmann Bernhard R, Yusuf Salim, Eikelboom John W

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

In patients with chronic coronary or peripheral artery disease enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, randomised antithrombotic treatments were stopped after a median follow-up of 23 months because of benefits of the combination of rivaroxaban 2.5 mg two times per day and aspirin 100 mg once daily compared with aspirin 100 mg once daily. We assessed the effect of switching to non-study aspirin at the time of early stopping.

METHODS

Incident composite of myocardial infarction, stroke or cardiovascular death was estimated per 100 person-years (py) during randomised treatment (n=18 278) and after study treatment discontinuation to non-study aspirin (n=14 068).

RESULTS

During randomised treatment, the combination compared with aspirin reduced the composite (2.2 vs 2.9/100 py, HR: 0.76, 95% CI 0.66 to 0.86), stroke (0.5 vs 0.8/100 py, HR: 0.58, 95% CI 0.44 to 0.76) and cardiovascular death (0.9 vs 1.2/100 py, HR: 0.78, 95% CI 0.64 to 0.96). During 1.02 years after early stopping, participants originally randomised to the combination compared with those randomised to aspirin had similar rates of the composite (2.1 vs 2.0/100 py, HR: 1.08, 95% CI 0.84 to 1.39) and cardiovascular death (1.0 vs 0.8/100 py, HR: 1.26, 95% CI 0.85 to 1.86) but higher stroke rate (0.7 vs 0.4/100 py, HR: 1.74, 95% CI 1.05 to 2.87) including a significant increase in ischaemic stroke during the first 6 months after switching to non-study aspirin.

CONCLUSION

Discontinuing study rivaroxaban and aspirin to non-study aspirin was associated with the loss of cardiovascular benefits and a stroke excess.

TRIAL REGISTRATION NUMBER: NCT01776424.

Для цитирования: Dagenais Gilles R, Dyal Leanne, Bosch Jacqueline J, Leong Darryl P, Aboyans Victor, Berkowitz Scott D, Bhatt Deepak L, Connolly Stuart J, Fox Keith A A, Muehlhofer Eva, Probstfield Jeffrey L, Widimsky Petr, Winkelmann Bernhard R, Yusuf Salim, Eikelboom John W. Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.. Heart (British Cardiac Society). 2021. DOI: 10.1136/heartjnl-2020-318758.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.